Every material Form 8-K Edwards Lifesciences has filed with the SEC since July 24, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Edwards Lifesciences reported third-quarter 2026 sales of $1.72 billion, representing a 10.5% increase compared to the prior year. Driven by strong procedure volumes and robust performance across its businesses, the company raised its full-year 2026 sales growth and adjusted EPS guidance.
Q3 sales grew 10.5% to $1.72 billion, with constant currency sales up 11.2%.
Q3 EPS was $0.53, while adjusted EPS reached $0.80, up 19% versus the prior year.
Full-year 2026 sales growth guidance was increased to approximately 11.5% from the previous 10% to 11% range.
Adjusted EPS guidance for 2026 was raised to a range of $2.97 to $3.05.
Edwards Lifesciences said Donald E. Bobo, Jr., its Corporate Vice President, Strategy and Corporate Development, will retire by mid-year 2027. The company will begin searching for a successor, with the transition expected during 2027. Mr. Bobo is expected to stay on as a consultant through the end of 2027.
Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, will retire by mid-year 2027
A selection process for a successor begins promptly; the transition of duties is expected during 2027
Mr. Bobo is expected to remain as a consultant through the end of 2027
Edwards Lifesciences reported second-quarter 2026 sales of $1.74 billion, up 13.6% from a year earlier, and raised its full-year 2026 sales growth guidance to 10% to 11% on a constant currency basis. GAAP diluted EPS fell to $0.42 from $0.56 because of a $188.2 million tax valuation allowance tied to California budget legislation, while adjusted EPS rose to $0.78 from $0.67 and full-year adjusted EPS guidance of $2.95 to $3.05 was reaffirmed.
Q2 2026 net sales were $1.74 billion, up from $1.53 billion in Q2 2025; TAVR sales were $1.26 billion, up 11.3%.
GAAP diluted EPS was $0.42 versus $0.56 a year earlier, including a $188.2 million valuation allowance against deferred tax assets.
Full-year 2026 sales growth guidance was raised to 10% to 11% from 9% to 11%; adjusted EPS guidance of $2.95 to $3.05 was reaffirmed.
For Q3 2026, Edwards projects total sales of $1.63 billion to $1.71 billion and adjusted EPS of $0.71 to $0.77.
At its May 7, 2026 annual meeting, Edwards Lifesciences stockholders approved an amendment to the Long-Term Stock Incentive Compensation Program that adds 7,000,000 shares, bringing the total share limit to 341,500,000. Stockholders also elected all nine director nominees and approved the advisory vote on named executive officer compensation and the auditor ratification.
Share limit under the Long-Term Stock Program rises by 7,000,000 shares to 341,500,000 shares.
Stockholder approval of the amended program: 456,675,201 for and 19,210,539 against.
All nine director nominees were elected, including David T. Feinberg, MD, and Bernard J. Zovighian.
Advisory executive pay proposal passed with 424,961,639 for and 50,924,101 against.
Edwards Lifesciences said on May 4, 2026 that Theodora Mistras, currently CFO of Viatris, will become corporate vice president and chief financial officer effective May 29, 2026, succeeding Scott Ullem, who has held the role since 2014. The Offer Letter sets a $925,000 base salary, a $2,013,000 sign-on bonus, and an $8,000,000 initial RSU grant, with a $4,500,000 target fiscal 2026 annual equity award, which shareholders can use to gauge the cost of the leadership change.
Mistras, age 44, has been CFO of Viatris since March 1, 2024; previously a managing director at Citigroup and Goldman Sachs healthcare investment banking.
Offer Letter dated May 2, 2026: $925,000 base salary and target annual bonus of not less than 100% of base salary, plus a $2,013,000 sign-on bonus.
Initial RSU award with a grant date value of $8,000,000, vesting 43.75%, 50% and 6.25% on the first, second and third anniversaries of her start date.
Scott Ullem announced his planned transition in October; the press release says he will continue as a strategic advisor in the months ahead.
Edwards Lifesciences reported first-quarter 2026 sales of $1.65 billion, up 16.7% from a year earlier, and GAAP diluted EPS of $0.66. The company raised its full-year 2026 sales growth guidance to 9% to 11% and the midpoint of its adjusted EPS guidance, and it completed a $500 million accelerated share repurchase.
Q1 sales grew 16.7% to $1.65 billion (12.7% on a constant currency basis); TAVR sales were $1.20 billion and TMTT sales were $173 million.
Q1 GAAP diluted EPS was $0.66 versus $0.61 a year earlier; adjusted EPS was $0.78 versus $0.64.
Full-year 2026 sales growth guidance raised to 9% to 11% from 8% to 10%; adjusted EPS guidance range is $2.95 to $3.05 versus $2.90 to $3.05 previously.
The company completed a $500 million accelerated share repurchase and has about $1.5 billion remaining under its authorization.
Edwards Lifesciences reported fourth-quarter 2025 net sales of $1.57 billion, up 13.3% from a year earlier, with TAVR sales up 12.0% and TMTT sales up more than 40%. Profit fell sharply on a GAAP basis: net income from continuing operations was $64.2 million, or $0.11 per diluted share, versus $345.0 million, or $0.58, a year earlier, after a $208.6 million litigation charge and a $99.8 million impairment on its JenaValve investment. The company said it has increased confidence in its 2026 outlook, including adjusted EPS of $2.90 to $3.05.
Q4 2025 net sales $1.57 billion, up 13.3% (11.6% constant currency); adjusted EPS $0.58 versus $0.59 a year earlier
GAAP diluted EPS from continuing operations $0.11, versus $0.58 in Q4 2024, reflecting $208.6 million in intellectual property and litigation expenses and a $99.8 million impairment loss
2026 guidance: constant currency sales growth of 8% to 10% and adjusted EPS of $2.90 to $3.05, with management citing increased confidence
Q1 2026 outlook: total sales of $1.55 billion to $1.63 billion and adjusted EPS of $0.70 to $0.76
Edwards Lifesciences said its Chief Financial Officer, Scott Ullem, has decided to transition from his role by mid-year 2026. The company is starting a search for a new CFO, and Ullem will stay on in an advisory role after the successor is appointed.
Scott Ullem, CFO, informed the company of his decision on October 30, 2025
Transition is planned for no later than mid-year 2026
Company is initiating a selection process to appoint a new CFO
Ullem will continue in an advisory role after a new CFO is appointed
Edwards Lifesciences reported third-quarter 2025 sales of $1.55 billion, up 14.7% from a year earlier, and raised its full-year sales growth and adjusted EPS guidance. GAAP earnings per share fell to $0.50 from $0.61, and adjusted EPS was $0.67, matching the prior year, so shareholders receive higher sales expectations alongside lower reported profit.
Q3 sales were $1.55 billion, up 14.7% (12.6% adjusted); TAVR sales were $1.15 billion, up 12.4%.
GAAP diluted EPS was $0.50 versus $0.61 a year earlier; adjusted diluted EPS was $0.67 in both periods.
Full-year 2025 sales growth guidance rose to the high end of 9% to 10%; adjusted EPS guidance is $2.56 to $2.62, up from the high end of $2.45 to $2.55.
Q3 included $90.4 million in certain litigation expenses and a $40.0 million intangible assets impairment charge.
Edwards Lifesciences said Larry L. Wood, Corporate Vice President and Group President for Transcatheter Aortic Valve Replacement and Surgical Structural Heart, will resign effective September 1, 2025 to take a senior role at a company outside cardiovascular. Daniel J. Lippis, currently Corporate Vice President for Japan, Greater China and Asia Pacific, will take over as Corporate Vice President responsible for Transcatheter Aortic Valve Replacement on the same date.
Larry L. Wood notified the board on July 21, 2025 of his resignation
Resignation takes effect September 1, 2025
Daniel J. Lippis will assume responsibility for Transcatheter Aortic Valve Replacement
The filing does not disclose a replacement for Lippis's Japan, Greater China and Asia Pacific role
Edwards Lifesciences reported second-quarter 2025 sales of $1.53 billion, up 11.9% from a year earlier, and adjusted EPS of $0.67. The company raised its full-year 2025 sales growth guidance to 9% to 10% and its adjusted EPS outlook to the high end of $2.40 to $2.50. GAAP net income attributable to Edwards fell to $333.2 million from $366.3 million, partly due to a $47.1 million impairment loss.
Q2 sales $1.53 billion, up 11.9%; TAVR sales $1.1 billion, up 8.9%; TMTT sales $134.5 million, up 61.9%
Full-year 2025 sales guidance raised to 9% to 10%, or $5.9 billion to $6.1 billion; TAVR sales guidance raised to $4.3 billion to $4.5 billion
Adjusted diluted EPS $0.67 in Q2; full-year adjusted EPS now expected at the high end of $2.40 to $2.50
Q2 GAAP diluted EPS $0.56 versus $0.61 a year earlier, including a $47.1 million loss on impairment
At its annual meeting on May 8, 2025, Edwards Lifesciences stockholders elected nine director nominees, approved an advisory vote on named executive officer compensation, and ratified PricewaterhouseCoopers LLP as auditor for fiscal 2025. Stockholders also approved increases to the share reserves of the company's U.S. and international employee stock purchase plans.
U.S. ESPP share reserve increased by 4,200,000 shares; International ESPP increased by 1,460,000 shares
Executive pay advisory vote approved: 412,893,480.47 for and 56,265,224.07 against
PricewaterhouseCoopers LLP ratified as independent auditor for the year ending December 31, 2025: 447,661,338.99 for and 49,958,008.47 against
Edwards Lifesciences reported first-quarter 2025 sales of $1.41 billion, up 6.2% from a year earlier, and GAAP earnings per share from continuing operations of $0.62, up from $0.54. The company raised its 2025 total sales guidance to $5.7 to $6.1 billion and its TMTT sales guidance to $530 million to $550 million, while reaffirming adjusted EPS guidance of $2.40 to $2.50. Management said operating margin is expected to face pressure from the weaker dollar, announced tariffs and the expected JenaValve acquisition close.
Q1 sales were $1.41 billion, up 6.2%; TMTT sales rose 58% to $115 million.
GAAP diluted EPS from continuing operations was $0.62 versus $0.54 a year earlier; adjusted EPS was $0.64.
2025 total sales guidance raised to $5.7 to $6.1 billion; adjusted EPS guidance of $2.40 to $2.50 reaffirmed.
Q2 2025 outlook: total sales of $1.45 to $1.53 billion and adjusted EPS of $0.59 to $0.65.
Edwards Lifesciences reported fourth-quarter 2024 results on February 11, 2025, with net sales up 9% to $1.39 billion and GAAP diluted EPS of $0.58, compared with $0.55 a year earlier. The company reiterated its 2025 sales and adjusted EPS guidance and gave first-quarter 2025 projections, so the results and outlook are steady for shareholders.
Q4 2024 net sales were $1,385.8 million, up from $1,266.4 million a year earlier.
Q4 2024 GAAP diluted EPS was $0.58 versus $0.55; adjusted diluted EPS was $0.59.
2025 guidance reiterated: constant currency sales growth of 8% to 10% and adjusted EPS of $2.40 to $2.50.
Q1 2025 outlook: total sales of $1.35 billion to $1.43 billion and adjusted EPS of $0.58 to $0.64.
Edwards Lifesciences reported third-quarter 2024 net sales of $1.35 billion, up 9% from a year earlier, with adjusted EPS of $0.67 versus $0.55. It reiterated its 2024 full-year sales growth guidance of 8% to 10% and gave fourth-quarter sales and EPS ranges. GAAP diluted EPS of $5.13 was driven mainly by a one-time gain from discontinued operations tied to the Critical Care sale.
Q3 net sales $1,354.4 million, up 8.9% from $1,243.4 million; TMTT sales up 73%, TAVR up 6%
Edwards reported second-quarter sales of $1,385.9 million, up 7%, and GAAP diluted EPS of $0.61 versus $0.50 a year earlier. It cut full-year TAVR sales growth guidance to 5 to 7% from 8 to 10%, raised TMTT guidance to the higher end of $320 to $340 million, and agreed to buy JenaValve and exercise its option to buy Endotronix for about $1.2 billion in cash plus up to $445 million in milestone payments.
Q2 net sales of $1,385.9 million, up 7% from $1,295.5 million; TMTT sales rose 75% to $83 million
Full-year 2024 TAVR sales growth guidance lowered to 5 to 7% from 8 to 10%; total Edwards sales growth guidance kept at 8 to 10%
Acquisitions of JenaValve and Endotronix carry about $1.2 billion upfront cash plus up to $445 million on milestones, subject to closing conditions
Critical Care sale for $4.2 billion remains on track to close in late Q3 2024
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Edwards Lifesciences filing is on SEC EDGAR ↗. 8-K briefs of other companies →